2 citations
,
April 2021 in “Canadian Journal of Urology” This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
13 citations
,
November 2016 in “The Journal of urology/The journal of urology” In a population-based study, over 72,000 older men were examined, and dutasteride showed no increased risk of heart failure, myocardial infarction, or stroke compared to finasteride, as reported by the researchers.
21 citations
,
October 2015 in “Current Drug Targets” This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.
20 citations
,
January 2004 in “PubMed Central” This article reviews the use of 5α-reductase inhibitors for treating benign prostatic hyperplasia, suggesting potential benefits beyond symptom relief, but it reports no new clinical results.
12 citations
,
January 1998 in “Drug safety” Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.
11 citations
,
January 1995 in “Biomedicine & pharmacotherapy” This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.